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Summary
Background In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are 
widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare eﬃ   cacy 
and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an efavirenz-based regimen in co-
infected patients.
Methods We did a multicentre, open-label, randomised, non-inferiority trial at three health centres in Maputo, 
Mozambique. We enrolled adults (≥18 years) with tuberculosis and previously untreated HIV infection (CD4 cell counts 
<250 cells per μL) and alanine aminotransferase and total bilirubin concentrations of less than ﬁ  ve times the upper limit 
of normal. 4–6 weeks after the start of tuberculosis treatment, we randomly allocated patients (1:1) with central 
randomisation, block sizes of two to six, and stratiﬁ  ed by site and CD4 cell count to nevirapine (200 mg twice daily) or 
efavirenz (600 mg once daily), plus lamivudine and stavudine. The primary endpoint was virological suppression at 
48 weeks (HIV-1 RNA <50 copies per mL) in all patients who received at least one dose of study drug (intention-to-treat 
population); death and loss to follow-up were recorded as treatment failure. The non-inferiority margin for the diﬀ  erence 
of eﬃ   cacy was 10%. We assessed eﬃ   cacy in intention-to-treat and per-protocol populations and safety in all patients who 
received study drug. This study is registered with ClinicalTrials.gov, number NCT00495326.
Findings Between October, 2007, and March, 2010, we enrolled 285 patients into each group. 242 (85%) patients in the 
nevirapine group and 233 (82%) patients in the efavirenz group completed follow-up. In the intention-to-treat 
population, 184 patients (64·6%, 95% CI 58·7–70·1) allocated nevirapine achieved virological suppression at week 
48, as did 199 patients (69·8%, 64·1–75·1) allocated efavirenz (one-sided 95% CI of the diﬀ  erence of eﬃ   cacy 11·7%). 
In the per-protocol population, 170 (70·0%, 63·8–75·7) of 243 patients allocated nevirapine achieved virological 
suppression at week 48, as did 194 (78·9%, 73·2–83·8) of 246 patients allocated efavirenz (one-sided 95% CI 15·4%). 
The median CD4 cell count at randomisation was 89 cells per μL. 15 patients substituted nevirapine with efavirenz 
and six patients substituted efavirenz with nevirapine. 20 patients allocated nevirapine (7%) had grade 3–4 increase of 
alanine aminotransferase compared with 17 patients allocated efavirenz (6%). Three patients had severe rash after 
receipt of nevirapine (1%) but no patients did after receipt of efavirenz. 18 patients in the nevirapine group died, as 
did 17 patients in the efavirenz group.
Interpretation Although non-inferiority of the nevirapine-regimen was not shown, nevirapine at full dose could be a 
safe, acceptable alternative for patients unable to tolerate efavirenz.
Funding French Research Agency for HIV/AIDS and hepatitis (ANRS).
Introduction
Tuberculosis is the main opportunistic infection and a 
leading cause of death in people living with HIV. 
Antiretroviral therapy reduces mortality in patients co-
infected with HIV and tuberculosis and should be started 
during the ﬁ   rst 8 weeks of tuberculosis treatment, 
irrespective of the patient’s CD4 cell count.
1 Nevirapine 
and efavirenz are non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) recommended by WHO as ﬁ  rst-line 
antiretroviral therapy.
1 Nevirapine is the most commonly 
used drug in resource-poor countries with a high HIV 
burden because of the convenience and aﬀ  ordability of 
generic ﬁ  xed-dose combinations.
Rifampicin is a key component of tuberculosis treat-
ment but also a potent inducer of some forms of hepatic 
cytochrome P450, leading to enhanced NNRTI drug 
clearance and, consequently, reduced drug exposure. 
Nevirapine biotransformation pathways are more sen-
sitive to induction than are those of efavirenz, and 
nevirapine-based regimens therefore have a greater risk 
of subtherapeutic NNRTI concentrations.
2–5 The reduc-
tion in nevirapine concentration is most pronounced 
during the ﬁ  rst 2 weeks of antiretroviral therapy, when it 
is typically prescribed at half dose (200 mg lead-in dose) 
to prevent hypersensitivity before a steady state con-
centration has been reached.
6 To avoid this problem, 
WHO guidelines recommend efavirenz rather than 
nevirapine for patients co-infected with HIV and 
tuberculosis.
1 However, efavirenz has other diﬃ   culties, 
primarily its toxic eﬀ  ects on the CNS that can necessitate 
discontinuation of early treatment.
7 Moreover, because of 
efavirenz’s potential teratogenicity, use during the ﬁ  rst 
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trimester of pregnancy is controversial.
1,8,9 For national 
HIV programmes, ﬁ  xed-dose combinations containing 
efavirenz (efavirenz-lamivudine-tenofovir and efavirenz-
tenofovir-emtricitabine) are less aﬀ  ordable than are ﬁ  xed-
dose combinations based on nevirapine.
10
Assessment of the eﬀ  ects of giving rifampicin with 
nevirapine on virological outcome has yielded conﬂ  icting 
results in clinical studies of nevirapine given with a 
2 week lead-in dose.
11–14 These discrepancies led some 
authors to propose that, because cytochrome P450 
enzymes in patients on rifampicin are presumably 
already induced at the time of antiretroviral therapy 
initiation, nevirapine should be started at full dose in 
these patients.
15,16 However, eﬃ     cacy and safety of this 
approach have not been assessed. In this study, we aimed 
to compare the eﬃ   cacy and safety of nevirapine-based 
and efavirenz-based antiretroviral therapies in patients 
co-infected with HIV and tuberculosis, with initiation of 
nevirapine at full dose.
Methods
Study design and participants
The comparison of nevirapine and efavirenz for 
the treatment of HIV-tuberculosis co-infected patients 
(French Research Agency for HIV/AIDS and hepatitis 
[ANRS] 12146 CARINEMO) trial was an open-label, 
randomised, phase 3 non-inferiority trial done at three 
health centres in Maputo, Mozambique: José Macamo 
Hospital, Mavalane Hospital, and Alto Maé Health 
Centre. We enrolled adults (≥18 years) with previously 
untreated HIV infection who had been receiving 
treatment for pulmonary or extrapulmonary tuberculosis 
for less than 4 weeks at tuberculosis or HIV outpatient 
clinics in three health areas of Maputo. We enrolled 
participants if they had a Karnofsky score of 60% or more 
(ambulatory patients), CD4 cell count of less than 
250 cells per μL, a negative urine pregnancy test, alanine 
aminotransferase and total bilirubin concentrations of 
less than ﬁ  ve times the upper limit of normal (ULN; 
grade <3), and absence of any grade 4 clinical or biological 
adverse event. Women who had previously received one 
dose of nevirapine or zidovudine–nevirapine for 
prevention of mother-to-child trans  mission of HIV were 
eligible for inclusion.
We followed good clinical practice guidelines and 
four ethics committees approved the study protocol: the 
Comité Nacional de Bio-Ética para a Saúde (Maputo, 
Mozambique), the Médecins Sans Frontières Ethics 
Review Board (Zurich, Switzerland), the Comité de 
Protection des Personnes (Saint Germain-en-Laye, 
France), and the Columbia University ethics review 
committee (New York, NY, USA). All participants 
provided signed informed consent.
Randomisation and masking
4–6 weeks after starting tuberculosis treatment, 
we randomly allocated patients (1:1) to receive either 
nevirapine or efavirenz regimens. Randomisation was 
done centrally at Epicentre headquarters (Paris, France) 
and treatment allocation was communicated to the site 
investigators sequentially for consecutive enrolment of 
patients. The allocation sequence was computer- 
generated with block sizes of two to six (in steps of two), 
stratiﬁ  ed by site and CD4 cell count (≤50 cells per μL vs 
>50 cells per μL). Randomisation lists were prepared by 
the trial statistician (EB) and concealed from the site 
investigators. Masking of investigators and patients to 
treatment allocation would have required use of placebo 
and was not feasible in this context. Before closure of 
the trial sites, aggregated data by treatment group were 
available only to the trial statistician and the independent 
data monitoring committee (IDMC).
Procedures
All patients received the standard national tuberculosis 
chemotherapy of a generic ﬁ   xed-dose combination of 
once-daily tablets combining rifampicin (150 mg), 
isoniazid (75 mg), pyrazinamide (400 mg), and 
ethambutol (275 mg) for the ﬁ  rst 2 months, followed by 
isoniazid (75 mg) and rifampicin (150 mg) for the 
subsequent 4 months (Lupin, Aurangabad, India), at a 
dose of 10 mg/kg (rifampicin), 5 mg/kg (isoniazid), 
25 mg/kg (pyrazinamide), and 15 mg/kg (ethambutol). 
Antiretroviral therapy was started after patients received 
2 weeks of counselling, which involved psychosocial 
Figure 1: Study proﬁ  le
*One patient was incarcerated during follow-up, one had an exacerbation of a chronic psychotic disorder that 
prevented retention in the trial, and one had baseline monoresistance to rifampicin and was referred to the 
national multidrug-resistant tuberculosis programme.
285 allocated to nevirapine 285 allocated to efavirenz
570 randomly allocated
Disposition at week 48
242 completed follow-up
         240 with HIV-1 RNA result at week 48
               2 without HIV-1 RNA result at week 48
     4 lost to follow-up
   18 died
      3 withdrew because of multidrug resistance
   15 voluntary withdrawal
      3 other reasons of withdrawal*
Disposition at week 48
233 completed follow-up
         230 with HIV-1 RNA result at week 48
               3 without HIV-1 RNA result at week 48
     8 lost to follow-up
   16 died
      1 withdrew because of multidrug resistance
   27 voluntary withdrawal
573 enrolled
3 started on efavirenz without randomisation
702 assessed for eligibility
  20 declined to participate
101 did not meet inclusion criteria
     8 otherArticles
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support and education about adherence to antiretroviral 
therapy and tuber  culosis therapy. Participants in the 
nevirapine group received one tablet of ﬁ  xed-dose 
combination nevirapine (200 mg), lamivudine (150 mg), 
and stavudine (30 mg; Cipla, Patalganga, India) twice-
daily, which was replaced by nevirapine (200 mg), 
lamivudine (150 mg), and zidovudine (300 mg; 
Aurobindo, Heydarabad, India) in August, 2010, to 
comply with new national and inter  national 
recommendations. Patients in the efavirenz group 
received one tablet per day of efavirenz (600 mg; 
Aurobindo, Andrah Pradesh, India) combined with one 
tablet twice-daily of the ﬁ  xed-dose  combination 
lamivudine (150 mg) and stavudine (30 mg; Cipla, Goa, 
India), replaced by lamivudine (150 mg) and zidovudine 
(300 mg; Cipla) in August, 2010. All drugs were WHO 
prequaliﬁ  ed.
17 The protocol allowed substitution of 
nevirapine by efavirenz in cases of severe hepatitis 
(alanine aminotransferase >5×ULN) or rash (grade ≥3), 
and substitution of efavirenz by nevirapine during the 
ﬁ   rst trimester of pregnancy for women who became 
pregnant during follow-up. Tenofovir replaced stavudine 
or zidovudine in patients who developed lactic acidosis, 
as measured by lactic acid concentration in symptomatic 
patients, and in patients co-infected with hepatitis B and 
presenting with severe hepatitis. According to 2006 WHO 
and national guidelines, patients with HIV-1 RNA counts 
of more than 10  000 copies per mL on two consecutive 
measures and reinforcement of treatment adherence 
were switched to an adapted boosted protease inhibitor-
based antiretroviral therapy after approval by the national 
antiretroviral committee. All patients received pyridoxine 
(50 mg per day) during tuberculosis treatment and 
960 mg co-trimoxazole per day.
We did clinical examination and laboratory analyses at 
screening and inclusion visits, at weekly visits for the 
ﬁ  rst 8 weeks after randomisation, and thereafter every 
4 weeks. Patients were diagnosed with pulmonary 
tuberculosis and started tuberculosis treatment at clinics 
before referral to the trial site. Diagnosis of pulmonary 
tuberculosis was based on the results of two sputum 
smear-examination (on spot and early-morning speci-
mens) or chest radiograph and response to an antibiotic 
trial for patients with smear-negative pulmonary tuber-
culosis. Extrapulmonary tuberculosis was diagnosed 
with cytohistopathology, biochemical, and radiographical 
assessment. For patients with pulmonary tuberculosis, 
two sputum samples were collected at the ﬁ  rst  trial 
screening visit within 2 weeks after start of tuberculosis 
treatment and were shipped to the reference laboratory at 
the Institute of Tropical Medicine (Antwerp, Belgium) 
for culture and drug-susceptibility testing. Sputum-
microscopy was also done at 2, 4, and 6 months after start 
of tuberculosis treatment. We took chest radio  graphs and 
full blood counts at the screening visit for all patients.
We diagnosed hepatitis B (deﬁ   ned as detection of 
hepatitis B surface antigen and hepatitis B core antibody) 
and hepatitis C (deﬁ  ned as detection of hepatitis C virus 
antibody with two ELISA tests and conﬁ  rmation by the 
detection of hepatitis C virus-RNA at the Necker Hospital, 
Paris, France) at the inclusion visit. We measured plasma 
HIV-1 RNA with the Roche Cobas Amplicor HIV-1 monitor 
test v1.5 (Roche Diagnostics, Basel, Switzerland) at the 
inclusion visit and at weeks 12, 24, 36, and 48; CD4 cell 
count was assessed at screening visit, week 24, and 
week 48. Resistance mutations to nucleoside reverse 
transcriptase inhibitors and NNRTI were determined in 
all patients with HIV-1 RNA counts of more than 
400 copies per mL at week 48 by sequencing the reverse 
transcriptase gene with the consensus technique of the 
Nevirapine group (n=285) Efavirenz group (n=285)
Site
Alto Maé 100 (35%) 101 (35%)
Mavalane 112 (39%) 111 (39%)
José Macamo 73 (26%) 73 (26%)
Sex, female 125 (44%) 114 (40%)
Age, years 33 (29–41) 33 (28–40)
Weight, kg 51·7 (46·6–57·2) 52·5 (47·5–58·8)
Body-mass index, kg/m² 18·7 (17·1–20·2) 18·9 (17·6–20·3)
Karnofsky performance score
≥80 249 (87%) 261 (92%)
60–70 36 (13%) 24 (8%)
Pulmonary tuberculosis smear result
Positive 99 (35%) 121 (42%)
Negative or no microscopy results* 127 (45%) 97 (34%)
Extrapulmonary tuberculosis 59 (21%) 67 (24%)
Tuberculosis meningitis 1 (<1%) 0
Pleural tuberculosis 37 (13%) 35 (12%)
Miliary tuberculosis 9 (3%) 10 (4%)
Lymph node tuberculosis 9 (3%) 15 (5%)
Abdominal tuberculosis 2 (1%) 3 (1%)
Tuberculosis pericarditis 1 (<1%) 0
Bone tuberculosis 0 2 (1%)
Disseminated tuberculosis 0 3 (1%)
WHO stage 4 HIV infection other than 
extrapulmonary tuberculosis
19 (7%) 15 (5%)
Time between start of tuberculosis therapy and 
start of antiretroviral therapy, weeks
4·9 (4·4–5·1) 4·9 (4·4–5·1)
Laboratory ﬁ  ndings
Alanine aminotransferase, ULN 24·2 (15–39) 23·7 (16·3–37·8)
Bilirubin, mg/dL 0·44 (0·32–0·60) 0·46 (0·33–0·63)
Haemoglobin, g/dL 9·4 (8·4–10·2) 9·4 (8·3–10·4)
CD4 count, cells per μL 92 (44–148) 86 (44–140)
CD4 count, <50 cells per μL 81 (28%) 81 (28%)
HIV-RNA, log10 copies per mL 5·7 (5·1–6·1) 5·5 (5·2–6·1)
HBV surface antigen 59/284 (21%) 63/281 (22%)
HCV antibody 4/284 (1%) 5/284 (2%)
Data are n (%), median (IQR), or n/N (%). ULN=upper limit of normal. HBV=hepatitis B virus. HCV=hepatitis C virus. 
*19 patients in the nevirapine group and 11 patients in the efavirenz group were not able to produce sputum specimen 
for microscopy test.
Table 1: Baseline characteristics of the intention-to-treat populationArticles
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AC11 ANRS resistance group at the Necker Hospital 
(Paris, France). We measured alanine aminotransferase 
and total bilirubin concentrations at screening visits and 
at weeks 2, 4, 6, 8, 12, 16, 20, 24, 36, and 48. At every follow-
up visit, we monitored adherence to antiretroviral therapy 
and tuberculosis treatment with an analogue visual scale, 
questionnaire, and pill count. In addition, we used the 
isoniazid urine test (BBL Taxo isoniazid test; Becton 
Dickinson, Franklin Lakes, USA) to assess tuberculosis 
treatment adherence. 
We assessed intensity of adverse events with the ANRS 
table for grading adult adverse event (grade 1 was deﬁ  ned 
as mild, grade 2 as moderate, grade 3 as severe, and grade 
4 as lifethreatening).
18 We deﬁ  ned serious adverse events 
as any untoward medical occurrence that, at any dose, 
resulted in death, was life-threatening, required hospital 
admission or prolongation of hospital stay, resulted in 
disability or incapacity, or resulted in a congenital anomaly 
or birth defect. We obtained blood samples for 
measurement of nevirapine and efavirenz plasma 
concentration every 12 weeks. To verify the absence of 
major changes in metabolism of nevirapine caused by 
rifampicin, the IDMC requested a full pharmacokinetic 
analysis in the ﬁ  rst 20 patients enrolled in the nevirapine 
group 4 weeks after co-administration with rifampicin and 
also 4 weeks after completion of tuberculosis treat  ment.
19 
The protocol  was amended in January, 2010 to extend 
follow-up until week 96 for the last enrolled patients with 
HIV-1 RNA and CD4 cell count measured at 72 weeks and 
96 weeks (appendix). Results of the extended follow-up 
will be presented separately.
The primary outcome was virological suppression at 
week 48, deﬁ  ned as an HIV-1 RNA count of less than 
50 copies per mL. Patients who died or were lost to 
follow-up before week 48 were categorised as treatment 
failures. Secondary outcomes were increase in CD4 cell 
count by more than 20% from baseline to week 48, 
occurrence of AIDS-deﬁ  ning events, end of tuberculosis 
treatment outcomes as per WHO deﬁ  nitions, occur  rence 
of treatment-emergent adverse eﬀ  ects  (TEAE), 
and paradoxical tuberculosis immune reconstitution 
inﬂ  ammatory syndrome (IRIS) within 12 weeks of start 
of antiretroviral therapy.
20,21 Members of the trial’s 
scientiﬁ  c advisory board (RB and CM) validated causes of 
death and IRIS-tuberculosis. Adverse event terms were 
adopted from the medical dictionary for regulatory 
activities (MedDRA version 11.1).
22
Statistical analysis
We deﬁ  ned the non-inferiority margin for the diﬀ  erence 
in eﬃ     cacy as 10%. Assuming a 70% eﬃ   cacy  in  the 
efavirenz group
23 and a maximum diﬀ  erence of 10% in 
eﬃ   cacy between two groups, a sample size of 260 patients 
per group was needed to determine non-inferiority with 
a power of 80% and an α level of 5% (one-sided test; 
nQuery Advisor version 6). We increased the proposed 
sample size by 10% to account for loss to follow-up.
Data were reviewed by the IDMC every 6 months. We 
did eﬃ   cacy analyses for two populations: the intention-
to-treat population, which included all randomised 
patients who received at least one dose of allocated drug; 
and the per-protocol population, excluding participants 
who discontinued treatment prematurely for reasons 
other than death or loss to follow-up, who had a treatment 
adherence of less than 80%, who had NNRTI substitution, 
or who did not have HIV-1 RNA results at week 48. We 
did a sensitivity analysis of eﬃ   cacy in the intention-to-
treat population, classifying treatment failures as patients 
Figure 2: Overall success rates (non-inferiority analysis) in intention-to-treat and per-protocol populations
Diﬀ  erence of success rates between efavirenz and nevirapine regimens; bars show 90% CI. Dotted line shows the 
non-inferiority margin of 10%.
Favours nevirapine Favours efaviranz
Intention to treat
Per protocol 
Intention to treat (switch equals failure)
11·7 
15·4 
15·0 
20 15 5 01 0 –5 –10 –15 –20
Nevirapine group Efavirenz group Diﬀ  erence (%) One-sided 
(95% CI)
p value
n/N % (95% CI) n/N % (95% CI)
Primary analysis*
Intention to treat 184/285 64·6% (58·7–70·1) 199/285 69·8% (64·1–75·1) 5·3% 11·7 ··
Per protocol 170/243 70·0% (63·8–75·7) 194/246 78·9% (73·2–83·8) 8·9% 15·4 ··
Intention to treat (switch equals failure) 171/285 60·0% (54·1–65·7) 195/285 68·4% (62·7–73·8) 8·4% 15·0 ··
Secondary analysis
Death 18/285 6·3% (3·8–9·8) 16/285 5·6% (3·2–9·0) ·· ·· 0·7236
HIV1-RNA <400 copies per mL† 187/243 76·9% (71·1–82·1) 202/246 82·1% (76·7–86·7) ·· ·· 0·1573
CD4 gain ≥20% 223/285 78·2% (73·0–82·9) 213/285 74·7% (69·3–79·7) ·· ·· 0·3233
New AIDS-deﬁ  ning diseases 19/285 6·7% (4·1–10·2) 22/285 7·7% (4·9–11·4) ·· ·· 0·6267
*Virological suppression at week 48. †In the per-protocol population.
Table 2: Eﬃ   cacy outcomes
See Online for appendixArticles
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who had NNRTI substitution, including substitution 
because of pregnancy (switch equals failure analysis). We 
tested non-inferiority of the nevirapine regimen with the 
Blackwelder method by calculating the diﬀ  erence  in 
eﬃ   cacy between the efavirenz and nevirapine regimens 
and comparing the upper limit of the 90% CI (as speciﬁ  ed 
in the sample-size calculation based on a one sided-test 
and a 5% α error) to the non-inferiority margin.
24 
Therefore, to accept non-inferiority of the nevirapine 
regimen, the upper limit of the 90% CI needed to be 
equal or less than 10%. Secondary analyses included 
estimation of the proportion of patients with HIV-1 RNA 
levels of less than 50 copies per mL at weeks 12, 24, 36, 
and 48. For patients who had NNRTI substitution, we 
used only HIV-1 RNA results before substitution. Other 
secondary analyses included antiretroviral therapy 
eﬃ   cacy at 48 weeks with an HIV-1 RNA detection limit of 
400 copies per mL in the per-protocol population; the 
proportion of patients with an increase in CD4 cell count 
by 20% or more from baseline to week 48; the proportion 
of patients with an incident AIDS-deﬁ  ning disease; and 
end of tuberculosis treatment outcomes and the 
proportion of tuberculosis with paradoxical IRIS. For 
safety analysis, we report the proportion of patients who 
had at least one TEAE, major TEAE (grade ≥3), serious 
TEAE, or TEAE of interest (grade ≥3 hepatitis and rash) 
by treatment group. We report the proportion of patients 
with an increase of alanine aminotransferase (grade ≥2) 
during follow-up and by group. We compared proportions 
with χ² or Fisher’s exact tests with two-sided p values. 
Data were analysed with Stata version 10.1.
This study is registered with ClinicalTrials.gov, number 
NCT00495326.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. EB had full access to all the data in 
the study and MB had ﬁ  nal responsibility for the decision 
to submit for publication.
Results
We enrolled 573 patients between October, 2007, and 
March, 2010, and completed follow-up in February, 2011 
(ﬁ  gure 1). Because of a temporary hold on inclusions 
placed by the IDMC in October, 2007, which was justiﬁ  ed 
by the investigators’ decision to abandon the 2 week 
nevirapine lead-in dose on the basis of preliminary 
results from a large South African prospective cohort,
14 
three patients were started on efavirenz regimen without 
randomisation. 43 (15%) of 285 patients randomly allo-
cated nevirapine and 52 (18%) of 285 patients randomly 
allocated efavirenz did not complete 48 weeks of follow-
up (p=0·3118).
In the nevirapine group, 17 patients discontinued 
follow-up before 12 weeks (13 deaths, three losses to 
follow-up, and one referral to treatment for multidrug-
resistant tuberculosis), 12 discontinued follow-up at 
12–24 weeks (seven voluntary withdrawals, four referrals 
to treatment for multidrug-resistant tuber  culosis, one 
death, and one referral to psychiatric treatment), and 
14 discontinued follow-up after 24 weeks (eight voluntary 
withdrawals, four deaths, one loss to follow-up, and one 
incarceration). In the efavirenz group, 15 patients 
discontinued follow-up before 12 weeks (eight deaths, 
three losses to follow-up, three voluntary withdrawals, 
and one referral to treatment for multidrug-resistant 
tuberculosis); 20 discontinued follow-up at 12–24 weeks 
(11 voluntary withdrawals, ﬁ  ve deaths, and four losses to 
follow-up) and 17 discontinued follow-up after 24 weeks 
(13 voluntary withdrawals, three deaths, and one loss to 
follow-up). Of 42 voluntary withdrawals, 18 moved to 
South Africa and 13 moved to another region in 
Mozambique for work reasons, ten refused to continue 
follow-up in the trial, and one was unable to participate 
because of drug addiction. Fewer patients withdrew 
voluntarily in the nevirapine group (15 patients [5%]) 
than in the efavirenz group (27 patients [9%]; p=0·0544). 
15 patients substituted from nevirapine to efavirenz 
(14 because of toxic eﬀ  ects and one because of protocol 
deviation) and six patients substituted from efavirenz to 
nevirapine (four because of pregnancy and two because 
of neurological toxic eﬀ  ects).
Table 1 shows baseline characteristics of patients. 
Although not signiﬁ  cantly  diﬀ   erent, slightly fewer 
patients had smear-positive pulmonary tuberculosis in 
the nevirapine group than the efavirenz group (p=0·0584). 
The median time between start of tuberculosis treatment 
and sputum collection for Mycobacterium tuberculosis 
culture was 14 days (IQR 8–20) for nevirapine and 12 days 
(7–18) for efavirenz. After exclusion of failure of specimen 
shipment (12 samples in the nevirapine group vs 
Figure 3: Patients with HIV-1 RNA counts less than 50 copies per mL during follow-up
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14 samples in the efavirenz group), culture contam  inated 
results (13 vs 15), and mycobacteria other than tuberculosis 
(one  vs ﬁ   ve), cultures were positive in 58 (29%) of 
200 patients with pulmonary tuberculosis in the 
nevirapine group and 69 (38%) of 183 patients in the 
efavirenz group (p=0·0707).
Two patients were allocated the incorrect drug because 
of an incorrect stratiﬁ  cation by CD4 cell count but were 
retained in the intention-to-treat population. After 
exclusion of patients who discontinued prematurely for 
reasons other than death or loss to follow-up (voluntary 
withdrawals, withdrawals due to multidrug resistance, or 
other reasons; ﬁ  gure 1), patients with NNRTI substitution, 
patients with antiretroviral therapy adherence lower than 
80% (four patients in the nevirapine group vs two patients 
in the efavirenz group), and patients who completed 
follow-up but did not have an HIV-1 RNA measurement 
at week 48 (two vs three), we included 243 patients from 
the nevirapine group and 246 patients from the efavirenz 
group in the per-protocol analysis.
Antiretroviral therapy eﬃ   cacy (HIV-1 RNA <50 copies 
per mL) at 48 weeks was 64·6% for nevirapine and 69·8% 
for efavirenz in the intention-to-treat population and 
70·0% vs 78·9% in the per-protocol population (ﬁ  gure 2 
and table 2). Non-inferiority of the nevirapine regimen 
was not shown. The one-sided 95% CI of the efavirenz-
nevirapine eﬃ   cacy  diﬀ   erence exceeded the predeﬁ  ned 
10% non-inferiority margin in intention-to-treat, per-
protocol, and switch-equals-failure analysis (ﬁ  gure 2 and 
table 2). 15 patients who substituted nevirapine with 
efavirenz had virological suppression at week 48. Two of 
four patients who substituted efavirenz with nevirapine 
because of pregnancy had no virological suppression at 
week 48 and one had conﬁ  rmed NNRTI resistance.
Although the proportion of patients with an HIV-1 
RNA count of less than 50 copies per mL was lower in 
the nevirapine group than in the efavirenz group, the 
diﬀ  erence was not signiﬁ  cant beyond 12 weeks (ﬁ  gure 3). 
Incidence of AIDS-deﬁ  ning illness, increase in CD4 cell 
count, and the proportion of patients at week 48 with an 
HIV-1 RNA count of less than 400 copies per mL did not 
diﬀ  er between groups (table 2).
Antiretroviral resistance genotyping results (table 3) 
were available for 49 (79%) of 62 patients who had HIV-1 
RNA levels of more than 400 copies per mL at week 48. 
All reverse transcriptase gene sequences corresponded to 
HIV-1 subtype C.
Tuberculosis treatment success (cured or completed) 
was more than 90% in both groups (table 4). 32 patients 
in the nevirapine group (11%) and 21 in the efavirenz 
group (7%) had paradoxical associated tuberculosis IRIS 
(p=0·1039).
The number of TEAEs was much the same in both 
groups (table 5). 18 patients in the nevirapine group died, 
as did 17 patients in the efavirenz group (one patient 
allocated efavirenz died without been randomly allocated). 
Cause of death was determined for 29 (83%) of 35 deaths 
and included tuberculosis (three deaths in the nevirapine 
group  vs ﬁ   ve in the efavirenz group), severe infection 
(three  vs  three), IRIS-tuberculosis (four vs none), IRIS-
Kaposi (one vs one), Kaposi sarcoma (two vs two), wasting 
syndrome (none vs two), tumour of hypopharynx (none vs 
one), Guillain-Barré syndrome (none  vs  one), and car 
accident (one vs none). No deaths were attributed to the 
study drugs. The proportion of patients with an increase 
of alanine aminotransferase during follow-up was much 
the same in both groups (ﬁ  gure 4). One patient in the 
nevirapine group had Stevens-Johnson syndrome that 
resolved after discontinuation of nevirapine. More patients 
in the nevirapine group (14 patients) than in the efavirenz 
group (two) dis  continued because of toxic eﬀ  ects 
(p=0·002; table 5). 11 patients received tenofovir during 
follow-up (four for severe hepatitis with hepatitis B co-
infection and seven for lactic acidosis or severe neuropathy 
with anaemia).
Discussion
To our knowledge, our study is the largest randomised 
non-inferiority trial to compare the eﬃ   cacy of nevirapine-
based and efavirenz-based regimens in patients co-
infected with HIV and tuberculosis, and the ﬁ  rst to use 
Nevirapine 
group
Efavirenz 
group
p value
HIV-1 RNA >50 copies per mL 56 31 ··
HIV-1 RNA >400 copies per mL  37 25 ··
No sample 2 7 ··
No ampliﬁ  cation 2 2 ··
Samples tested for resistance 33 16 ··
NNRTI resistance mutations* 27 (82%) 11 (69%) 0·5073
Etravirine resistance mutations* 8 (24%) 3 (19%) 0·9465
184V mutation 22 (67%) 9 (56%) 0·4781
TAMs 5 (15%) 1 (6%) 0·6696
TAM=tumour-associated macrophage. NNRTI=non-nucleoside reverse 
transcriptase inhibitors. ANRS= French Research Agency for HIV/AIDS and 
hepatitis. *NNRTI resistance mutations according to the ANRS algorithm.
18
Table 3: Resistance data by study group at week 48
Nevirapine group 
(n=285)
Efavirenz group 
(n=288)
Treatment success 260 (91%) 260 (90%)
Cured 131 (46%) 142 (49%)
Treatment completed 129 (45%) 118 (41%)
Death 13 (5%) 14 (5%)
Defaulter 6 (2%) 11 (4%)
Treatment failure 1 (<1%) 2 (1%)
Transferred* 5 (2%) 1 (<1%)
Treatment outcomes did not diﬀ  er between the two study groups. *Five patients 
were transferred to the national multidrug-resistant tuberculosis programme for 
treatment and one patient was incarcerated during follow-up.
Table 4: Tuberculosis treatment outcomes in the safety populationArticles
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nevirapine without a lead-in dose. Non-inferiority of the 
nevirapine-regimen was not shown in our intention-to-
treat or per-protocol populations. However, rates of 
immune reconstitution, death, and incident AIDS events 
did not diﬀ  er between the two groups. Our switch-equals-
failure analysis in the intention-to-treat population 
favoured the efavirenz regimen, which resulted in 
six treatment substitutions compared with 15 for patients 
randomly allocated to receive the nevirapine regimen. All 
substitutions were made because of safety reasons or 
pregnancy and none was attributed to loss of eﬃ   cacy.
Several reasons might explain why nevirapine did not 
show non-inferiority. One possibility is that the two tested 
regimens have the same eﬃ   cacy, and that the rifampicin 
interaction drives the diﬀ  erence in virological response. 
Indeed, the large non-inferiority randomised clinical 
2NN trial
23 comparing nevirapine-based and efavirenz-
based regimens in patients with HIV but not tuberculosis 
reported no signiﬁ  cant diﬀ  erences in virological eﬃ   cacy 
between groups at 48 weeks (HIV-1 RNA threshold of 
50 copies per mL). A Cochrane meta-analysis
25 of seven 
randomised clinical trials (60% of participants were from 
the 2NN study
23) also failed to show a signiﬁ  cant 
diﬀ  erence between the two regimens. The 2NN study
23 
thus could not show the non-inferiority of the nevirapine-
based regimen. However, several ﬁ  ndings from our study 
suggest that the signiﬁ  cant  diﬀ   erence in virological 
response between the two groups could have been 
attributable to nevirapine’s lower intrinsic potency rather 
than to the interaction with rifampicin. First, the 
diﬀ  erence remained the same during and after tuber-
culosis treatment (which was discontinued at week 24) 
and seemed more pronounced at week 48. Second, 
although not representative of all patients, the nevirapine 
trough concentrations from the ﬁ  rst 20 patients enrolled 
in the trial showed a median minimum concentration of 
4·9 mg/L, which is higher than the minimum thera-
peutic concentration of 3 mg/L.
19 Finally, the 48 week 
eﬃ   cacy of the nevirapine regimen in our study (64·6%) 
 Nevirapine 
group (n=285)
Efavirenz 
group (n=288)
Treatment-emergent adverse events 284 (>99%) 280 (97%)
Major adverse event 74 (26%) 70 (24%)
Serious adverse events* with ≥1% 
frequency
53 (19%) 53 (18%)
Blood and lymphatic system disorders
Anaemia 7 (2%) 9 (3%)
Leukopenia 3 (1%) 2 (1%)
Neutropenia 4 (1%) 2 (1%)
Gastrointestinal disorders
Diarrhoea 5 (2%) 3 (1%)
General disorders and administration-site conditions
Fatigue 11 (4%) 17 (6%)
Oedema 2 (1%) 3 (1%)
Immune system disorders
Immune reconstitution syndrome 5 (2%) 2 (1%)
Hypersensitivity 3 (1%) 0
Infections and infestations
Abscess 2 (1%) 3 (1%)
Pulmonary tuberculosis 0 3 (1%)†
Investigations
Increased alanine 
aminotransferase 
8 (3%) 13 (5%)
Nervous system disorders
Headache 4 (1%) 2 (1%)
Respiratory, thoracic, and mediastinal disorders
Dyspnoea 7 (2%) 7 (2%)
Haemoptysis 0 3 (1%)
Skin and subcutaneous tissue disorders
Rash 4 (1%) 0
Adverse event of interest
Increased ALT grade ≥2 59 (21%) 55 (19%)
Increased ALT grade ≥3 20 (7%) 17 (6%)
Rash grade ≥2 21 (7%) 24 (8%)
Rash grade ≥3 3 (1%) 1 (<1%)
Rash grade ≥2 and increased ALT 
or bilirubin grade ≥3
4 (1%) 3 (1%)
Rash grade ≥3 and increased ALT 
or bilirubin grade ≥2
3 (1%) 1 (<1%)
Adverse event leading to NNRTI substitution
Hepatitis 11 (4%) 0
Rash 3 (1%) 0
Acute psychiatric disorders 0 2 (1%)
Hepatitis was graded as an increase of ALT or bilirubin of 1·25–2·50×ULN 
(grade 1), >2·50–5·00×ULN (grade 2), >5·00–10·00×ULN (grade 3), and 
>10·00×ULN (grade 4). NNRTI=non-nucleoside reverse transcriptase inhibitor. 
ALT=alanine aminotransferase. ULN=upper limit of normal. *By system organ 
class and preferred term according to Medical Dictionary for Regulatory Activities 
coding.
22 †Two recurrences and one death from tuberculosis.
Table 5: Treatment-emergent adverse events, serious adverse events, 
and adverse events of interest in the safety population
Figure 4: Patients presenting with an increase of alanine aminotransferase of grade 2 or grade 3 intensity 
during follow-up in the safety population
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was in the range (61–69%) reported from randomised 
trials that used the same regimen in patients with HIV 
without tuberculosis co-infection.
23,26–28 The hypothesis 
that nevirapine has a lower intrinsic antiviral potency 
than does efavirenz is also supported by recent results of 
the HIV-CAUSAL prospective cohort
29 which reported 
54% more virological failures in patients after 12 months 
on an nevirapine regimen than on an efavirenz regimen, 
and by a review
30 of studies comparing nevirapine and 
efavirenz in tenofovir-based regimens, which concluded 
that nevirapine regimens also show increased rates of 
virological failure.
Our results diﬀ   er from those obtained in the two 
previous randomised trials comparing nevirapine-based 
and efavirenz-based regimens in patients co-infected 
with HIV and tuberculosis (panel). The N2R study
13 from 
Thailand did not report diﬀ  erences in 48 week eﬃ   cacy 
between the nevirapine (71·8%) and efavirenz (73·2%) 
regimens in their intention-to-treat population. However, 
the trial was not suﬃ   ciently powered (140 patients) to 
show non-inferiority of the nevirapine regimen. The 
second study, a non-inferiority trial from India,
11 was 
halted by the IDMC because of a lower eﬃ   cacy noted in 
the nevirapine group (65%; once-daily nevirapine) than 
in the efavirenz group (85%) at week 24 with an HIV-1 
RNA threshold of 400 copies per mL. A post-hoc analysis 
with the same cutoﬀ   in our trial did not show a signiﬁ  cant 
diﬀ  erence: 219 (77%) of 285 pa  tients in the nevirapine 
group versus 230 (81%) of 285 in the efavirenz group 
(p=0·2599). These conﬂ  icting results might be explained 
by diﬀ  erences in nevirapine admin  istration (once-daily vs 
twice-daily or whether escalating dosage was used), 
methodological diﬀ  erences,  diﬀ   er  ences in treatment 
adherence, and genetic diﬀ  erences in NNRTI disposition 
that lead to variability between individuals in plasma 
clearance, eﬀ  ect, and tolerance.
31
Although introduced at full dose, nevirapine was well 
tolerated in our study, with a low rate of severe biological 
hepatic toxicity (7%) compared with the 10% average 
reported in previous trials of patients with HIV without 
tuberculosis co-infection, and the proportion of severe 
rash was very low (1%).
32 This low incidence of rash was 
probably attributable to the low baseline CD4 cell counts in 
patients starting treatment in this trial but might be also 
explained by a genetic variation of nevirapine metabolism, 
resulting in diminished plasma concentration of the 
metabolite 12 hydroxy-nevirapine, which is associated with 
a lower risk of nevirapine-induced rash.
33
Our trial has several limitations. First, despite 
appropriate randomisation (baseline characteristics did 
not diﬀ  er between the two groups), slightly fewer patients 
with smear-positive pulmonary tuberculosis were 
enrolled in the nevirapine group than in the efavirenz 
group. Second, the proportion of patients who had 
pulmonary tuberculosis conﬁ  rmed with M tuberculosis 
culture was low in comparison with microscopy results. 
In Mozambique, such culturing is not part of routine 
tuberculosis diagnosis. However, in this trial it was done 
once patients were referred to the trial sites, on average, 
2 weeks after the start of tuberculosis treatment, whereas 
microscopy tests were done before tuberculosis treatment 
was started at the clinic. Because of this delay, some 
cultures might have tested negative. Moreover, the 
challenges of shipping sputum samples abroad for this 
test resulted in a high rate of specimen contamination 
(7%). Third, several patients withdrew from the trial after 
migrating to South Africa during follow-up and were no 
longer able to access the study sites. Most of these 
patients left the trial after 24 weeks of follow-up and 
slightly more voluntary withdrawals occurred in the 
efavirenz arm, which could not be explained. 
Nonetheless, such a pattern of withdrawal is unlikely to 
be related to a poor efavirenz tolerability because most 
withdrawals occurred after 24 weeks after the start of 
antiretroviral therapy. Fourth, the risk of bias in 
investigators’ management of an open-label design 
should not be ignored. However, the eﬃ   cacy outcome 
and hepatitis, one of the main safety outcomes, were 
established principally from laboratory results. Finally, 
the choice of a predeﬁ  ned 10% non-inferiority margin 
merits discussion. Some investigators, suggest adoption 
of a larger non-inferiority eﬃ   cacy margin of 12% with 
95% power on the basis of HIV trials in previously 
untreated patients that suggest such trials are often 
overpowered because of an underestimation of the 
success rates and that a loss of eﬃ   cacy could be accepted 
Panel: Research in context
Systematic review
We searched PubMed for randomised controlled trials published in English between Jan 1, 
1970, and Nov 31, 2012, with the following search string: (“tuberculosis”[Text Word]) 
AND “nevirapine”[Text Word]) OR (“tuberculosis”[Text Word] AND “non-nucleoside 
reverse transcriptase inhibitor”[Text Word]) OR (“antiretroviral therapy”[Text Word] AND 
“tuberculosis”[Text Word]). We identiﬁ  ed only two randomised controlled trials that 
compared nevirapine-based and efavirenz-based antiretroviral therapies in patients 
co-infected with HIV and tuberculosis treated with rifampicin.
11,13 One of these trials
11 
assessed once-daily nevirapine and was prematurely halted because of the reduced 
eﬃ   cacy (65%) in the nevirapine group compared with the efavirenz group (85%) at week 
24. The other trial
13 did not show a signiﬁ  cant diﬀ  erence in the 48 week virological 
eﬃ   cacy between the nevirapine and efavirenz groups but was not powered to show 
non-inferiority of the nevirapine regimen. In both trials, the nevirapine-escalating dose 
was used, which could result in subtherapeutic nevirapine concentrations at antiretroviral 
therapy initiation in patients on rifampicin.
Interpretation
To our knowledge, our trial is the ﬁ  rst to compare a nevirapine regimen with an efavirenz 
regimen in patients co-infected with HIV and tuberculosis without use of a nevirapine 
escalating dose and the ﬁ  rst to have suﬃ   cient power for a non-inferiority analysis. 
Although non-inferiority of the nevirapine regimen was not shown in our study, eﬃ   cacy 
results at 48 weeks were comparable with those reported for patients with HIV but not 
tuberculosis and the co-administration of nevirapine and rifampicin was well tolerated. 
Nevirapine might therefore be regarded as an acceptable alternative in patients unable to 
tolerate efavirenz or who have a contraindication to efavirenz.Articles
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if the new treatment has some other advantage.
34 In our 
trial, the estimated success rate was not underestimated 
but the choice of higher non-inferiority margin (12%) 
might have slightly changed the results of the trial but 
not the conclusion.
Few alternatives to efavirenz exist for patients co-
infected with HIV and tuberculosis. Use of a triple 
nucleoside reverse transcriptase inhibitor regimen is not 
ideal because of its reduced eﬃ   cacy (especially in patients 
with a high HIV-RNA at treatment initiation) compared 
with the efavirenz regimen in patients with HIV without 
tuberculosis.
1,23,35 Replacement of rifampicin by rifabutin, 
a weaker enzyme inducer, would preclude use of a ﬁ  xed-
dose combination-based tuberculosis therapy (a corner-
stone of the WHO tuberculosis control strategy), thereby 
making treatment much more expensive.
36 The use of a 
600 mg maintenance dose of nevirapine has been also 
suggested but was associated with an increased rate of 
hypersensitivity reactions and premature termination of 
a randomised trial from Thailand.
37
Overall, non-inferiority of the nevirapine regimen in 
terms of eﬃ   cacy for patients co-infected with HIV and 
tuberculosis was not shown in this trial. This outcome 
might be attributed to a slightly reduced intrinsic potency 
of nevirapine compared with efavirenz rather than to co-
administration with rifampicin. However, we also noted 
that initiation of nevirapine at full dose showed 48 week 
eﬃ     cacy results comparable with those reported for 
patients with HIV but not tuberculosis, and was well 
tolerated. Nevirapine could therefore be regarded as an 
acceptable alternative in patients unable to tolerate 
efavirenz or who have a contraindication to efavirenz.
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